Ruth March
- Pharmacology top 1%
- Pharmacogenetics and Drug Metabolism 6
-
- Computational Drug Discovery Methods 4
- Immunology top 10%
- Rheumatology top 5%
- Spondyloarthritis Studies and Treatments 2
- Systemic Lupus Erythematosus Research 2
- Statistics and Probability top 5%
-
- Genomics and Rare Diseases 3
- Genetic Associations and Epidemiology 3
- Genetic Mapping and Diversity in Plants and Animals 2
-
- Pharmaceutical Economics and Policy 3
- Co-authors
- Paul MorganMenelas N. PangalosDavid CookDearg S. BrownRobert AlexanderHelen AmbroseRaeanne C. MooreYu Chen
- Partner nations
- United KingdomUnited StatesSweden
In The Last Decade
Ruth March
29 papers receiving 2.0k citations
Hit Papers
Peers
Comparison fields: 5 of 132
- Pharmacology 280
- Computational Theory and Mathematics 359
- Immunology 300
- Rheumatology 173
- Statistics and Probability 82
Countries citing papers authored by Ruth March
This map shows the geographic impact of Ruth March's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruth March with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruth March more than expected).
Fields of papers citing papers by Ruth March
This network shows the impact of papers produced by Ruth March. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruth March. The network helps show where Ruth March may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ruth March, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2022 | 14 | |
| 2 | 2021 | 1 | |
| 3 | 2019 | 1 | |
| 4 | Impact of a five-dimensional framework on R&D productivity at AstraZenecabreakdown → | 2018 | 271 |
| 5 | Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional frameworkbreakdown → | 2014 | 891 |
| 6 | 2010 | 11 | |
| 7 | 2006 | 46 | |
| 8 | 2005 | 372 | |
| 9 | 2005 | 5 | |
| 10 | 2005 | 9 | |
| 11 | 2005 | 7 | |
| 12 | 2004 | 73 | |
| 13 | 2003 | 1 | |
| 14 | 2002 | 25 | |
| 15 | 2001 | 8 | |
| 16 | 2000 | 22 | |
| 17 | 2000 | 33 | |
| 18 | 2000 | 3 | |
| 19 | 1999 | 18 | |
| 20 | 1959 | 11 |
About Ruth March
Ruth March is a scholar working on Pharmacology, General Dentistry, Immunology, Genetics and Computational Theory and Mathematics, having authored 29 papers that have together received 2.1k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (6 papers), Computational Drug Discovery Methods (4 papers), Genomics and Rare Diseases (3 papers), Genetic Associations and Epidemiology (3 papers), Pharmaceutical Economics and Policy (3 papers), Spondyloarthritis Studies and Treatments (2 papers), Genetic Mapping and Diversity in Plants and Animals (2 papers) and Systemic Lupus Erythematosus Research (2 papers). The work is most often cited by research in Pharmacology (280 citations), Computational Theory and Mathematics (359 citations), Immunology (300 citations), Rheumatology (173 citations) and Statistics and Probability (82 citations). Ruth March has collaborated with scholars based in United Kingdom, United States and Sweden. Frequent co-authors include Paul Morgan, Menelas N. Pangalos, David Cook, Dearg S. Brown, Robert Alexander, Helen Ambrose, Raeanne C. Moore, Yu Chen, Dennis W. Schneck and Julie Zalikowski. Their work appears in journals such as Pharmacogenomics, Yeast, Nature Reviews Drug Discovery, Scientific Reports and Pharmacogenetics and Genomics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.